Is Axim Biotechnologies Inc (AXIM) a Stock to Watch After Losing 0.00% This Week?

Overall market sentiment has been down on Axim Biotechnologies Inc (AXIM) stock lately. AXIM receives a Bearish rating from InvestorsObserver Stock Sentiment Indicator.

Axim Biotechnologies Inc has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on AXIM!

See Full AXIM Report

What is Stock Sentiment?

Sentiment is a very short-term indicator that is entirely technical. There is no information about the health of profitability of the underlying company in our sentiment score. As a technical indicator, news about the stock, or company, such as an earnings release or other event, could move the stock counter to the recent trend. Sentiment is how investors, or the market, feels about a stock. There are lots of ways to measure sentiment. At the core, sentiment is pretty easy to understand. If a stock is going up, investors must be bullish, while if it is going down, sentiment is bearish. InvestorsObserver’s Sentiment Indicator looks at price trends over the past week and also considers changes in volume. Increasing volume can mean a trend is getting stronger, while decreasing volume can mean a trend is nearing a conclusion. For stocks that have options, our system also considers the balance between calls, which are often bets that the price will go up, and puts, which are frequently bets that the price will fall.

What's Happening With AXIM Stock Today?

Axim Biotechnologies Inc (AXIM) stock is flat 0% while the S&P 500 is up 0.09% as of 11:22 AM on Thursday, Mar 28. AXIM is unchanged $0.00 from the previous closing price of $0.01 on volume of 66,550 shares. Over the past year the S&P 500 has risen 32.28% while AXIM has fallen -66.67%. AXIM lost -$0.03 per share in the over the last 12 months. To see InvestorsObserver's Sentiment Score for Axim Biotechnologies Inc click here.

More About Axim Biotechnologies Inc

Axim Biotechnologies Inc is a vertically integrated research and development company focused on improving the landscape for diagnosis of ophthalmological conditions such as Dry Eye Disease through rapid diagnostic tests. Additionally, it owns IP and has conducted research on SARS-CoV-2 (COVID-19) rapid neutralizing antibody tests to detect levels of functional neutralizing antibodies that are believed to prevent SARS-CoV-2 from entering the host cells, as well as for oncological indications. Click Here to get the full Stock Report for Axim Biotechnologies Inc stock.